Healthcare Services

Global Hereditary Transthyretin Amyloidosis Market Forecast 2026–2035 Presenting Long-Term Industry Expansion Insights

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Hereditary Transthyretin Amyloidosis Market By 2030 Starting From Its 2026 Size?

The market size for hereditary transthyretin amyloidosis has shown strong growth over recent years. It is anticipated to expand from $1.49 billion in 2025 to $1.62 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. The expansion observed in the past can be ascribed to factors such as increased clinical recognition of attr amyloidosis, the availability of tafamidis therapy, the proliferation of specialized neurology and cardiology centers, enhanced genetic testing for ttr mutations, and the emergence of more patient registry programs.

The market for hereditary transthyretin amyloidosis is anticipated to experience substantial expansion in the coming years. By 2030, its valuation is projected to reach $2.28 billion, reflecting an 8.9% compound annual growth rate (CAGR). This projected growth during the forecast period is fueled by several factors, including the proliferation of next-generation gene therapies, increased funding for rare disease research, broader integration of precision medicine techniques, the advancement of CRISPR-based treatments, and refined technologies for monitoring disease outcomes. Key developments expected during this period involve the increasing uptake of gene silencing therapies, a surge in the application of RNAi-based treatments, a heightened emphasis on early detection of cardiac and neurological symptoms, the availability of more oral treatment choices, and improved long-term disease management frameworks.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22003&type=smp

What Primary Drivers Are Shaping The Development Of The Hereditary Transthyretin Amyloidosis Market?

The expanding geriatric population is anticipated to fuel the growth of the hereditary transthyretin amyloidosis market in the coming years. This demographic encompasses individuals aged 65 and older, who frequently require specialized medical attention and support as they age. The rise in this population segment is a result of increasing life expectancy, driven by advancements in healthcare and improved living conditions. Hereditary transthyretin amyloidosis (hATTR) markedly affects the geriatric population by inducing progressive neuropathy and cardiomyopathy, contributing to higher morbidity rates among older individuals. For instance, according to the US-based nonprofit organization, Population Reference Bureau, in January 2024, the US population aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, signifying a 47% rise. Therefore, the burgeoning geriatric population is a primary driver for the expansion of the hereditary transthyretin amyloidosis market.

Which Segment Categories Define The Hereditary Transthyretin Amyloidosis Market?

The hereditary transthyretin amyloidosis market covered in this report is segmented –

1) By Type: Oral, Subcutaneous Injection, Other Types

2) By Drug Class: RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Oral: Tafamidis, Experimental Oral Therapies

2) By Subcutaneous Injection: Inotersen, Vutrisiran

3) By Other Types: Intravenous Therapies, Gene Silencing Therapies, CRISPR-Based Therapies

What Major Market Trends Are Driving Changes In The Hereditary Transthyretin Amyloidosis Market?

Leading companies within the hereditary transthyretin amyloidosis market are creating novel treatments, including RNAi therapeutics, aimed at lowering the production of transthyretin (TTR) protein. RNAi therapeutics represent a category of medications that utilize RNA interference technology to quiet particular genes, thereby diminishing the creation of proteins causing illness. As an illustration, in October 2024, Alnylam Pharmaceuticals, Inc., a US-based biopharmaceutical firm, presented a supplemental new drug application (sNDA) to the US FDA for Vutrisiran (AMVUTTRA) for treating transthyretin amyloidosis with cardiomyopathy. This submission highlights its cutting-edge RNAi therapeutic method, specifically crafted to target and lessen transthyretin (TTR) protein, which is crucial for disease advancement. Vutrisiran’s method of subcutaneous delivery provides a more convenient and patient-friendly dosing schedule compared to conventional intravenous therapies, positioning it as a potentially revolutionary choice for those suffering from this severe ailment.

Who Are The Top Companies Competing In The Hereditary Transthyretin Amyloidosis Market?

Major companies operating in the hereditary transthyretin amyloidosis market are Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Pfizer Inc., Eli Lilly and Company, Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Novartis AG, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb, Merck and Co Inc., Johnson and Johnson, AbbVie Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Amgen Inc.

Read the full hereditary transthyretin amyloidosis market report here:

https://www.thebusinessresearchcompany.com/report/hereditary-transthyretin-amyloidosis-global-market-report

How Does The Hereditary Transthyretin Amyloidosis Market Perform Across Major Global Regions?

North America was the largest region in the hereditary transthyretin amyloidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hereditary Transthyretin Amyloidosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22003&type=smp

Browse Through More Reports Similar to the Global Hereditary Transthyretin Amyloidosis Market 2026, By The Business Research Company

Atrophic Glossitis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/atrophic-glossitis-treatment-global-market-report

Progressive Ataxia And Weakness Disorders Global Market Report

https://www.thebusinessresearchcompany.com/report/progressive-ataxia-and-weakness-disorders-global-market-report

Alzheimers Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795